LJN 452 in pBAD

Study title: A double blind, randomized placebo controlled crossover multiple dose study of LJN452 to assess safety, tolerability and efficacy in patients with primary bile acid diarrhoea (pBAD).

The study is expected to last approximately 13 weeks. All participants in the trial will visit hospital at least eleven times over 13 weeks. There is one screening visit to confirm eligibility for the study and then participants will be randomised to one of two treatment groups.

REC reference:16/LO/0351

LJN 452 in pBAD